{'fraction_non_alphanumeric': 0.01881467544684854, 'fraction_numerical': 0.011288805268109126, 'mean_word_length': 5.186046511627907, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Debrisoquine hydroxylation test as an example of new possibilities of research in psychopharmacology].

About 5-10% of European white population has a genetically determinant defect of the CYP2D6, one of the enzymes of cytochrome P-450. This defect leads to the impaired metabolism of many drugs including various psychopharmacological agents. The measurement of the hydroxylation of debrisoquine is a laboratory test which allows to identify such an individual. Patients who show an impaired hydroxylation of debrisoquine usually demonstrate severe side effects and poor outcome of psychopharmacotherapy. This depends on whether the administered drug is metabolized the same way as debrisoquine, i.e. in the presence of CYP2D6. The diagnosis of the phenotype of debrisoquine hydroxylation before treatment may allow to select the group of poor metabolizers. This diagnosis can help to identify the appropriate treatment for those patients, i.e. the selection of either a drug which is not metabolized in the presence of CYP2D6 or an alternative form of therapy.